A running list of senior FDA officials who have left the agency

Taking stock of the drug industry, from the lab to the medicine chest

April 10, 2025 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Adobe STAT+ | Crucial FDA drug reviews expected to be slowed by job cuts A former top FDA official said it's only a matter of time before the chaos at the agency starts to impact drug reviews.  By Lizzy Lawrence, Matthew Herper, and Elaine Chen STAT+ | Arkansas may force companies to choose between running a PBM or pharmacies The legislation would mark the first of its kind to be signed in the U.S., if Gov. Sarah Sanders is on board. By Ed Silverman STAT+ | Gilead is urged to rework licensing deals for groundbreaking HIV prevention drug A group of academics argue voluntary licensing deals pursued by Gilead on lenacapavir are too restrictive, which will delay or deny access to the drug. By Ed Silverman Annie Rice/AP RFK Jr. suggests some vaccines are risky or ineffective, downplays measles threat The comments, dismissed by health experts, come as the HHS secretary faces a growing outbreak of measles that could test his leadership. By Daniel Payne

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser